Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE approves Herceptin for NHS

  • Comment

The use of the drug Herceptin has been recommended for use after NICE altered its draft guidance following the manufacturer’s submission of new evidence on the drug’s effectiveness.

NICE originally did not recommend the use of trastuzumab, which is sold under the trade name Herceptin, but now it has said the drug can be considered for use in some cases.

The drug’s manufacturer, Roche, presented extra evidence after NICE issued its original draft guidance.

NICE’s new draft guidance says the drug may be considered for use in patients who have a high level of a particular protein on the surface of cancer cells.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs